Last reviewed · How we verify

NCT04281316: HIGH-FLOW

High-Flow in Hypercapnic Stable COPD Patients

Terminated NA Last updated 24 May 2022
What this trial tests

NA trial testing Nasal High Flow installation in Adherence, Treatment in 3 participants. Terminated before completion.

Timeline
23 September 2020
Primary endpoint
16 December 2021
16 December 2021

Quick facts

Lead sponsorUniversity Hospital, Grenoble
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment3
Start date23 September 2020
Primary completion16 December 2021
Estimated completion16 December 2021
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Grenoble

Who can join

Adults 18 to 80, any sex, with Adherence, Treatment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Monocentric, prospective, open, randomized 1:1, controlled study to evaluate the impact of nasal high-flow (NHF) on nocturnal transcutaneous PCO2 (PtCO2) compared to non-invasive ventilation ± Long-Term Oxygen Therapy (LTOT) in patients with a Chronic obstructive pulmonary disease (COPD)-related hypercapnic respiratory failure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Adherence, Treatment

Currently open trials in the same condition.

Other University Hospital, Grenoble trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04281316.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing